Skip to main content
    C

    CareDx Inc (CDNA)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $73.72
    -4.16 (-5.34%)

    Market Cap: $4.09B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CareDx Inc (CDNA) Financials: Revenue, Profit and Cash Flow

    Updated Jul 30, 2026. Financial statements from company filings, amounts in US dollars.

    CareDx reported revenue of $379.81M for the fiscal year ended Dec 31, 2025, up 13.8% from the year before. That year, net income was -$21.35M with a net margin of -5.6%, operating cash flow was $42.03M and free cash flow was $36.12M. The quarter ended Jun 30, 2026 had revenue of $263.90M and net income of $110.64M.

    Revenue and Margins

    The operating margin was -8.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $40.63M, a compound annual rate of 28.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$379.81M+13.8%67.6%-8.1%-5.6%
    Dec 2024$333.79M+19.1%67.1%12.2%15.7%
    Dec 2023$280.32M-12.9%63.6%-72.5%-67.9%
    Dec 2022$321.79M+8.6%65.1%-24.0%-23.8%
    Dec 2021$296.40M+54.2%67.1%-10.0%-10.3%
    Dec 2020$192.19M+51.3%67.2%-11.7%-9.7%
    Dec 2019$127.07M+66.0%64.2%-19.3%-17.3%
    Dec 2018$76.57M+58.4%56.9%-20.3%-61.1%
    Dec 2017$48.32M+18.9%55.8%-42.0%-115.0%
    Dec 2016$40.63MN/A48.0%-91.9%-97.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$379.81M$333.79M$280.32M$321.79M$296.40M$192.19M$127.07M$76.57M$48.32M$40.63M
    Cost of revenue$123.24M$109.70M$102.07M$112.21M$97.39M$63.12M$45.45M$32.99M$21.37M$21.12M
    Gross profit$256.57M$224.09M$178.26M$209.58M$199.01M$129.08M$81.61M$43.58M$26.95M$19.51M
    Research and development$71.43M$72.51M$82.42M$90.39M$76.53M$48.94M$30.71M$14.51M$12.39M$12.38M
    Operating income-$30.78M$40.77M-$203.36M-$77.23M-$29.73M-$22.53M-$24.53M-$15.58M-$20.29M-$37.33M
    Net income-$21.35M$52.55M-$190.28M-$76.61M-$30.66M-$18.71M-$21.97M-$46.78M-$55.56M-$39.76M
    EBITDA-$8.57M$61.47M-$187.11M-$63.60M-$19.23M-$10.48M-$17.79MN/AN/A-$32.55M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$263.90M$117.70M$108.39M$100.06M$86.68M$84.69M$86.58M$82.88M$92.27M$72.05M$65.57M$67.19M
    Gross profit$228.93M$84.07M$72.87M$69.40M$58.02M$56.27M$58.39M$55.31M$64.28M$46.12M$39.89M$42.66M
    Operating income$113.22M$1.20M-$6.04M-$246.00K-$11.12M-$13.37M$84.38M-$13.72M-$7.33M-$22.57M-$122.63M-$28.78M
    Net income$110.64M$2.81M-$4.11M$1.68M-$8.57M-$10.35M$87.70M-$10.64M-$4.62M-$19.89M-$118.10M-$23.48M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $6.51M by $58.91M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$413.23M$491.05M$466.83M$542.99M$566.62M$368.51M$151.74M$130.70M$83.56M$76.73M
    Current assets$257.13M$351.83M$313.71M$387.85M$433.36M$273.10M$71.92M$81.11M$26.77M$26.67M
    Cash and equivalents$65.43M$114.69M$82.20M$89.92M$348.49M$134.67M$38.22M$64.62M$16.89M$17.26M
    Total liabilities$110.13M$112.62M$205.50M$112.08M$100.75M$90.83M$52.74M$34.77M$89.52M$56.97M
    Short-term debt$6.51M$6.10M$5.94M$5.59M$3.96M$2.03M$3.02M$172.00K$15.72M$22.85M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$18.34M$1.10M
    Shareholder equity$303.10M$378.43M$261.33M$430.91M$465.88M$277.68M$99.00M$95.93M-$6.13M$19.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$532.99M$411.06M$413.23M$432.31M$444.26M$489.64M$491.05M$476.99M$466.78M$452.41M$466.83M$501.18M
    Total liabilities$107.39M$97.53M$110.13M$121.17M$116.89M$110.29M$112.62M$203.74M$202.11M$196.18M$205.50M$107.05M
    Cash and equivalents$373.64M$77.92M$65.43M$91.44M$68.21M$88.75M$114.69M$95.40M$95.78M$93.30M$82.20M$75.98M
    Shareholder equity$425.60M$313.54M$303.10M$311.14M$327.37M$379.35M$378.43M$273.25M$264.67M$256.23M$261.33M$394.13M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 85.9% of operating cash flow. Share repurchases came to 243.0% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$42.03M$38.05M-$18.39M-$25.24M-$19.29M$33.43M-$2.77M-$4.01M-$14.31M-$16.52M
    Capital expenditures$5.91M$6.48M$8.34M$21.23M$13.56M$7.11M$2.20M$2.04M$186.00K$549.00K
    Free cash flow$36.12M$31.56M-$26.73M-$46.47M-$32.85M$26.32M-$4.97M-$6.04M-$14.49M-$17.07M
    Dividends paidN/AN/AN/AN/A$2.14M$1.37M$4.42M$26.76M$0$0
    Share repurchases$87.77M$522.00K$27.54M$642.00K$0$0N/AN/AN/AN/A
    Investing cash flow$2.16M-$483.00K$40.45M-$228.50M$47.71M-$100.39M-$22.58M-$7.93M-$6.11M-$21.12M
    Financing cash flow-$93.39M-$5.61M-$29.61M-$4.54M$185.64M$163.15M-$132.00K$50.27M$29.38M$24.93M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$30.60M$4.33M$21.36M$37.36M$9.89M-$26.58M$21.89M$12.52M$18.95M-$15.31M-$8.38M-$10.18M
    Capital expenditures$1.86M$3.82M$1.97M$1.30M$1.01M$1.63M$1.52M$1.69M$1.79M$1.49M$1.59M$1.62M
    Free cash flow$28.75M$514.00K$19.39M$36.05M$8.89M-$28.21M$20.37M$10.84M$17.16M-$16.80M-$9.97M-$11.80M
    Last 12 quarters

    Frequently Asked Questions About CDNA

    What is CareDx's annual revenue?

    CareDx reported revenue of $379.81M for the fiscal year ended Dec 31, 2025.

    How fast is CareDx's revenue growing?

    Revenue was up 13.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.7%.

    Is CareDx profitable?

    No. CareDx reported net income of -$21.35M for the fiscal year ended Dec 31, 2025, with a net margin of -5.6%.

    How much free cash flow does CDNA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $42.03M minus capital expenditures of $5.91M produced free cash flow of $36.12M.

    How much debt does CareDx have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $6.51M and cash and equivalents of $65.43M.